A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain
- PMID: 22996848
A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain
Abstract
Background: Tolerance is defined as a phenomenon in which exposure to a drug results in a decrease of an effect or the requirement of a higher dose to maintain an effect. The fear of a patient developing opioid tolerance contributes regularly to the stigmatization and withholding of intrathecal opioid therapy for chronic pain of non-cancer origin.
Objectives: The aim of this study was to describe the intrathecal opioid dose escalation throughout the years in chronic non-cancer pain patients. A secondary objective was the development of an intrathecal opioid dose predictive model.
Study design: Retrospective assessment of medical records.
Setting: Department of Pain Management, Russells Hall Hospital, Dudley, United Kingdom.
Methods: Medical records were reviewed and pump refill notes screened from the date of implant through November 2010 for 31 patients undertaking continuous intrathecal opioid therapy. All the patients included had undertaken a minimum of 6 years of intrathecal therapy when the data were collected.
Results: Significant increases in the intrathecal morphine dose were verified between follow-up at one year and all subsequent observations, F (2.075, 62.238) = 13.858, 0 < 0.001, but ceased to be significant from year 3 onwards, indicating stability of the morphine dose, F (3, 90) = 2.516, P = 0.63. A model that accounts for 76% of the variability of morphine doses at year 6 based on year 2 assessment combined with duration of pain prior to initiation of intrathecal therapy was developed: year 6 dose = -0.509 + (1.296 x [year 2 dose]) + (0.061 x [duration of pain]).
Limitations: Retrospective study.
Conclusion: The opioid dose escalation observed throughout the years was modest and not significant following year 3 of therapy. The model developed has the potential to assist the physician in the identification of a need for alternative treatment strategies. Furthermore, since many of the pump replacements are performed prior to year 6, it can also assist in the informed decision of the benefits and risks of the maintenance of this therapy.
Similar articles
-
Outcome of intrathecal opioids in chronic non-cancer pain.Eur J Pain. 2001;5(4):353-61. doi: 10.1053/eujp.2001.0255. Eur J Pain. 2001. PMID: 11743701
-
Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up.Pain Med. 2010 Jul;11(7):1010-6. doi: 10.1111/j.1526-4637.2010.00876.x. Epub 2010 May 18. Pain Med. 2010. PMID: 20492572
-
Age-dependent intrathecal opioid escalation in chronic noncancer pain patients.Pain Med. 2011 Aug;12(8):1179-89. doi: 10.1111/j.1526-4637.2011.01188.x. Epub 2011 Aug 2. Pain Med. 2011. PMID: 21810164
-
Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain.Pain Physician. 2011 Jul-Aug;14(4):343-51. Pain Physician. 2011. PMID: 21785477 Review.
-
Drug-related side effects of long-term intrathecal morphine therapy.Pain Physician. 2007 Mar;10(2):357-66. Pain Physician. 2007. PMID: 17387357 Review.
Cited by
-
Managing Chronic Non-Malignant Pain in the Elderly: Intrathecal Therapy.Drugs Aging. 2019 Sep;36(9):789-797. doi: 10.1007/s40266-019-00692-7. Drugs Aging. 2019. PMID: 31270686 Review.
-
Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.Support Care Cancer. 2014 Mar;22(3):795-801. doi: 10.1007/s00520-013-2036-8. Epub 2013 Nov 21. Support Care Cancer. 2014. PMID: 24258354
-
Current and Future Issues in the Development of Spinal Agents for the Management of Pain.Curr Neuropharmacol. 2017;15(2):232-259. doi: 10.2174/1570159x14666160307145542. Curr Neuropharmacol. 2017. PMID: 26861470 Free PMC article. Review.
-
Intrathecal Morphine Infusion Therapy in Management of Chronic Pain: Present and Future Implementation in Korea.Yonsei Med J. 2016 Mar;57(2):475-81. doi: 10.3349/ymj.2016.57.2.475. Yonsei Med J. 2016. PMID: 26847303 Free PMC article.
-
Randomised, double-blind controlled trial by dose reduction of implanted intrathecal morphine delivery in chronic non-cancer pain.BMJ Open. 2013 Jul 31;3(7):e003061. doi: 10.1136/bmjopen-2013-003061. BMJ Open. 2013. PMID: 23903811 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical